Nonetheless, a notable deficiency in existing research is the lack of evidence about the therapeutic effectiveness of GLP-1 agonists and SGLT2 inhibitors, especially in the treatment of lean NAFLD (16). This evidence concerns the gene SLC5A2 and metabolic dysfunction-associated steatotic liver disease.